Barclays’s Sionna Therapeutics SION Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$737K Sell
18,385
-29,787
-62% -$1.14M ﹤0.01% 2942
2025
Q4
$1.98M Buy
48,172
+30,529
+173% +$1.16M ﹤0.01% 2936
2025
Q3
$519K Sell
17,643
-5,379
-23% -$117K ﹤0.01% 3792
2025
Q2
$399K Buy
+23,022
New +$302K ﹤0.01% 3890

Other funds holding SION

Barclays's SION Position: Q1 2026 in Review

Barclays reduced its Sionna Therapeutics (SION) stake by 62% in Q1 2026, selling an estimated $1.14M and leaving 18,385 shares worth $737K. The position accounts for ﹤0.01% of the portfolio, ranked #2942.

Barclays first reported a position in SION in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.98M in Q4 2025. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Barclays held 18,385 shares of Sionna Therapeutics worth $737K as of Q1 2026.
  • Barclays sold 29,787 Sionna Therapeutics shares in Q1 2026, an estimated $1.14M.
  • Sionna Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2942 holding.
  • Barclays first reported a position in Sionna Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Barclays's Sionna Therapeutics position peaked at $1.98M in Q4 2025.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.